Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bringing up BIIB

Biogen Idec Inc. has been on a tear of late, boosted by its updated guidance last week, ongoing acquisition rumors fueled by the Federal Trade Commission's approval of a stock purchase by activist investor Carl Icahn in late August, and its stock buyback in early July.

Last Thursday, BIIB (Cambridge, Mass.) committed to maintaining its rates of both top and bottom line growth over the next three years. At the Thomas Weisel conference in Boston, the company offered guidance that revenues

Read the full 816 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers